newsfilter
← Latest News
GlobeNewswire·

Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer

BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersBDC-1001 administered to initial patients in Phase